ABSTRACT
Background
The Cancer Genome Atlas (TCGA) classification of genetic alterations in uveal melanoma is widely used for prognostication. We present novel observations on the impact of TCGA Group specifically for iris melanoma.
Methods
This was a retrospective cohort study at a tertiary referral ocular oncology center. All patients with a diagnosis of iris melanoma who underwent genetic evaluation and assessment for TCGA classification between 20 November 1995 and 5 April 2021 were included. The main outcome measures were visual acuity, secondary glaucoma, tumor recurrence, melanoma-related metastasis and death per TCGA group.
Results
There were a total of 78 patients included. The mean patient age was 49.6 years (median 53.0, range 3.0–85.0), mean tumor basal diameter was 6.7 mm (median 6.0, range 1.5–22.0), and mean tumor thickness was 2.6 mm (median 2.5, range 0.5–8.5). Cytology results confirmed iris melanoma (93%) or were inconclusive (7%). The TCGA groups included Group A (n = 36, 46%), Group B (n = 7, 9%), Group C (n = 34, 44%), and Group D (n = 1, 1%). There was no statistically significant difference in outcomes of visual acuity, tumor thickness reduction, secondary glaucoma, tumor recurrence, melanoma-related metastasis or death per individual TCGA group (A vs. B vs. C vs. D) and per bimodal comparison (A/B vs. C/D).
Conclusions
In this analysis, iris melanoma was classified as TCGA group A or B in 55% and as C or D in 45%. The TCGA classification was not predictive of melanoma-related metastasis or death.
Disclosure statement
The authors report no conflicts of interes. The authors alone are responsible for the content and writing of this article.
Author contributions
Elliot Cherkas—data acquisition, data analysis and manuscript preparation
Guy Negretti—research design, data interpretation and manuscript preparation
Jennifer Zeiger—data acquisition and manuscript preparation